In this editorial from Future Oncology the different types of endometrial cancer are appraised.
Browsing: tumor heterogeneity
Could intratumor heterogeneity be used as a biomarker to predict primary tumor responsiveness and improve initial systemic treatment? Read further in this Editorial from Biomarkers in Medicine.
Could genotyping of circulating tumor cells allow for a personalized approach to breast cancer management? Read more in this Editorial from Pharmacogenomics.
Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?
This review article from our partner journal CNS Oncology discusses intratumor heterogeneity of glioblastoma and the use of imaging modalities to monitor this dynamic state.
This opinion piece from Biomarkers in Medicine discusses the ongoing molecular dissection of anaplastic large cell lymphoma, with a particular emphasis on new genetic findings in ALK-negative disease.
From Biomarkers in Medicine, this excellent Perspective article details recent advances in our understanding of the clinical utility of cell-free DNA and the future directions for its use in cancer management.
Researchers have discovered both the cellular origin of PIK3CA-induced breast cancers and new information regarding the control of tumor heterogeneity.
This opinion piece summarizes the potential and challenges of comprehensive high-throughput genetic analyses in clinical samples of gastric cancer – strategies that could lead to the discovery of next-generation biomarkers for the disease.
In a groundbreaking study conducted by Cancer Research UK researchers, five distinct subtypes of prostate cancer have been identified.
Intratumor heterogeneity and clonal diversity pose a challenge for personalized management of patients with glioblastoma. This article reviews the relationship between clonal heterogeneity and outcome and the clinical significance of subclonal driver mutations.